Assuntos
Alergia e Imunologia/normas , Antiasmáticos/uso terapêutico , Asma/tratamento farmacológico , Produtos Biológicos/uso terapêutico , Guias de Prática Clínica como Assunto , Antiasmáticos/economia , Antiasmáticos/farmacologia , Asma/diagnóstico , Asma/economia , Asma/epidemiologia , Produtos Biológicos/economia , Produtos Biológicos/farmacologia , Criança , Efeitos Psicossociais da Doença , Resistência a Medicamentos , Glucocorticoides/farmacologia , Glucocorticoides/uso terapêutico , Humanos , Adesão à Medicação , Prevalência , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
Hymenoptera venom allergy (HVA) is one of the most frequent causes of anaphylaxis following a bee, vespid or ant sting. Real-life data regarding the management of HVA in children are lacking. To address this unmet need, we carried out a survey defining the current management of HVA in children among pediatric allergists in Italy. Educational investments on the improvement of the management of pediatric patients with HVA are urgently needed, and our analysis represents a relevant instrument in targeting a roadmap with this aim. The time for pediatric allergists to take action has come, and a task force from the Rare Allergic Diseases Commission of the Italian Society of Pediatric Allergy and Immunology is working on the topic to improve pediatricians' knowledge and optimize the care of these patients.
Assuntos
Alérgenos/efeitos adversos , Anafilaxia/terapia , Venenos de Artrópodes/efeitos adversos , Dessensibilização Imunológica/estatística & dados numéricos , Mordeduras e Picadas de Insetos/complicações , Alérgenos/administração & dosagem , Alérgenos/imunologia , Alergistas/normas , Alergistas/estatística & dados numéricos , Alergia e Imunologia/normas , Anafilaxia/diagnóstico , Anafilaxia/imunologia , Animais , Venenos de Artrópodes/administração & dosagem , Venenos de Artrópodes/imunologia , Criança , Competência Clínica/normas , Competência Clínica/estatística & dados numéricos , Dessensibilização Imunológica/métodos , Dessensibilização Imunológica/normas , Necessidades e Demandas de Serviços de Saúde/estatística & dados numéricos , Humanos , Himenópteros/imunologia , Mordeduras e Picadas de Insetos/imunologia , Mordeduras e Picadas de Insetos/terapia , Itália , Pediatras/normas , Pediatras/estatística & dados numéricos , Guias de Prática Clínica como Assunto , Padrões de Prática Médica/normas , Padrões de Prática Médica/estatística & dados numéricos , Inquéritos e Questionários/estatística & dados numéricosRESUMO
Background ISO 9001 and ISO 15189 have been established as continuative models for quality systems beyond national laws, mandatory standards and guidelines of expert associations regarding analytical and organisational performance of medical laboratories and transfusion services. Although widely used, their impact on laboratory performance has not been investigated. Methods We retrospectively analysed the results of 167 laboratories in 59 distributions of the Austrian red cell immunohaematology external quality assessment (EQA) scheme in the years 1999-2017. The performance for each parameter and trends of individual participants were compared with respect to certification or accreditation status of participants' quality systems and to laboratory type. Results Considering more than 52,000 EQA results, the absence or presence of a laboratory quality management system showed different error rates. Laboratories with ISO 9001 or ISO 15189 certification/accreditation had 0.7% incorrect results, while this rate was doubled without such quality systems (1.4%, p=0.0002). Statistically significant error reductions were seen upon ISO 9001/ISO 15189 implementation (1.3% before vs. 0.7% after; p=0.0468). Transfusion services had fewer errors (0.9%) compared to hospital and independent laboratories (both 1.2%). Conclusions Implementation and maintenance of quality systems according to ISO 9001 or ISO 15189 as well as laboratory specialisation result in better analytical performance as can be seen in immunohaematology EQA results. The conclusion is that these results apply to other laboratory tests and perhaps to other areas of health care.
Assuntos
Alergia e Imunologia/normas , Hematologia/normas , Laboratórios/normas , Garantia da Qualidade dos Cuidados de Saúde/normas , Áustria , Humanos , Controle de Qualidade , Estudos RetrospectivosRESUMO
BACKGROUND: Update of the 2010 published evidence-based S3 guideline on epidemiology, diagnostics, therapy and management of uncomplicated, bacterial, outpatient-acquired urinary tract infections in adult patients. The guideline contains current evidence for the rational use of antimicrobial substances, avoidance of inappropriate use of certain antibiotic classes and development of resistance. METHODOLOGY: The update was created under the leadership of the German Association of Urology (DGU). A systematic literature search was conducted for the period 01 January 2008 to 31 December 2015. International guidelines have also been taken into account. Evidence level and risk of bias were used for quality review. RESULTS: Updated information on bacterial susceptibility, success, collateral damage and safety of first- and second-line antibiotics was given. For the treatment of uncomplicated cystitis the first line antibiotics are fosfomycin trometamol, nitrofurantoin, nitroxoline, pivmecillinam, trimethoprim (with consideration of the local resistance rates). Fluoroquinolones and cephalosporins should not be used as first choice antibiotics. In the case of uncomplicated pyelonephritis of mild to moderate forms, preferably cefpodoxime, ceftibuten, ciprofloxacin or levofloxacin should be used as oral antibiotics. CONCLUSION: The updated German S3 guideline provides comprehensive evidence- and consensus-based recommendations on epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients. Antibiotic stewardship aspects have significantly influenced the therapeutic recommendations. A broad implementation in all clinical practice settings is necessary to ensure a foresighted antibiotic policy and thus t improve clinical care.
Assuntos
Antibacterianos/administração & dosagem , Infecções Bacterianas/epidemiologia , Infecções Bacterianas/prevenção & controle , Bacteriúria/epidemiologia , Bacteriúria/prevenção & controle , Guias de Prática Clínica como Assunto , Prevenção Secundária/normas , Alergia e Imunologia/normas , Infecções Bacterianas/diagnóstico , Bacteriúria/diagnóstico , Relação Dose-Resposta a Droga , Esquema de Medicação , Medicina Baseada em Evidências , Alemanha , Humanos , Prevalência , Fatores de Risco , Terapêutica , Urologia/normasRESUMO
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational drug therapies that is contributing significantly to advancing treatment in multiple disease areas, including inflammatory and autoimmune diseases, genetic deficiencies and cancer. Unfortunately, unwanted immunogenic responses to BPs, in particular those affecting clinical safety or efficacy, remain among the most common negative effects associated with this important class of drugs. To manage and reduce risk of unwanted immunogenicity, diverse communities of clinicians, pharmaceutical industry and academic scientists are involved in: interpretation and management of clinical and biological outcomes of BP immunogenicity, improvement of methods for describing, predicting and mitigating immunogenicity risk and elucidation of underlying causes. Collaboration and alignment of efforts across these communities is made difficult due to lack of agreement on concepts, practices and standardized terms and definitions related to immunogenicity. The Innovative Medicines Initiative (IMI; www.imi-europe.org), ABIRISK consortium [Anti-Biopharmaceutical (BP) Immunization Prediction and Clinical Relevance to Reduce the Risk; www.abirisk.eu] was formed by leading clinicians, academic scientists and EFPIA (European Federation of Pharmaceutical Industries and Associations) members to elucidate underlying causes, improve methods for immunogenicity prediction and mitigation and establish common definitions around terms and concepts related to immunogenicity. These efforts are expected to facilitate broader collaborations and lead to new guidelines for managing immunogenicity. To support alignment, an overview of concepts behind the set of key terms and definitions adopted to date by ABIRISK is provided herein along with a link to access and download the ABIRISK terms and definitions and provide comments (http://www.abirisk.eu/index_t_and_d.asp).
Assuntos
Hipersensibilidade a Drogas/prevenção & controle , Drogas em Investigação/normas , Guias como Assunto/normas , Terminologia como Assunto , Alergia e Imunologia/normas , Hipersensibilidade a Drogas/imunologia , Indústria Farmacêutica/organização & administração , Indústria Farmacêutica/normas , Drogas em Investigação/efeitos adversos , Drogas em Investigação/uso terapêutico , Humanos , Inovação Organizacional , Política Organizacional , Padrões de ReferênciaRESUMO
Anti-nuclear antibodies (ANA) are fundamental for the diagnosis of autoimmune diseases, and have been determined by indirect immunofluorescence assay (IIFA) for decades. As the demand for ANA testing increased, alternative techniques were developed challenging the classic IIFA. These alternative platforms differ in their antigen profiles, sensitivity and specificity, raising uncertainties regarding standardisation and interpretation of incongruent results. Therefore, an international group of experts has created recommendations for ANA testing by different methods. Two groups of experts participated in this initiative. The European autoimmunity standardization initiative representing 15 European countries and the International Union of Immunologic Societies/World Health Organization/Arthritis Foundation/Centers for Disease Control and Prevention autoantibody standardising committee. A three-step process followed by a Delphi exercise with closed voting was applied. Twenty-five recommendations for determining ANA (1-13), anti-double stranded DNA antibodies (14-18), specific antibodies (19-23) and validation of methods (24-25) were created. Significant differences between experts were observed regarding recommendations 24-25 (p<0.03). Here, we formulated recommendations for the assessment and interpretation of ANA and associated antibodies. Notably, the roles of IIFA as a reference method, and the importance of defining nuclear and cytoplasmic staining, were emphasised, while the need to incorporate alternative automated methods was acknowledged. Various approaches to overcome discrepancies between methods were suggested of which an improved bench-to-bedside communication is of the utmost importance. These recommendations are based on current knowledge and can enable harmonisation of local algorithms for testing and evaluation of ANA and related autoantibodies. Last but not least, new more appropriate terminologies have been suggested.
Assuntos
Alergia e Imunologia/normas , Anticorpos Antinucleares , Autoantígenos , Doenças Reumáticas/diagnóstico , Reumatologia/normas , Humanos , Testes Imunológicos/normas , Doenças Reumáticas/imunologia , Terminologia como AssuntoAssuntos
Humanos , Recém-Nascido , Lactente , Pré-Escolar , Criança , Saúde da Criança/estatística & dados numéricos , Saúde da Criança , Alergia e Imunologia/instrumentação , Alergia e Imunologia/organização & administração , Alergia e Imunologia/normas , Alergia e Imunologia/tendências , Anormalidades do Sistema Respiratório/prevenção & controleAssuntos
Alergia e Imunologia , Médicos , Alergia e Imunologia/educação , Alergia e Imunologia/normas , Alergia e Imunologia/tendências , Animais , Evolução Biológica , Desenhos Animados como Assunto , Equador , Espécies em Perigo de Extinção , Bolsas de Estudo , Tentilhões/genética , Tentilhões/fisiologia , Conhecimentos, Atitudes e Prática em Saúde , História do Século XIX , História do Século XX , Masculino , Marketing de Serviços de Saúde , Equipe de Assistência ao Paciente , Relações Médico-Paciente , Seleção Genética , Recursos HumanosAssuntos
Alergia e Imunologia/economia , Alergia e Imunologia/normas , Garantia da Qualidade dos Cuidados de Saúde/economia , Garantia da Qualidade dos Cuidados de Saúde/normas , Assistência Ambulatorial/economia , Assistência Ambulatorial/normas , Humanos , Sistema de Pagamento Prospectivo/normas , Estados UnidosRESUMO
The incidence of allergic disease is increasing, with one in three people now reported as having some kind of allergy. Allergy support groups are working to raise awareness of this increase and also to highlight the inadequacies in NHS allergy management services. This has implications for nursing practice, as nurses are involved in identification and documentation of patients' allergies as well as in the management of allergic reactions including anaphylaxis.
Assuntos
Promoção da Saúde/organização & administração , Hipersensibilidade/epidemiologia , Hipersensibilidade/prevenção & controle , Alergia e Imunologia/normas , Conscientização , Fundações/organização & administração , Humanos , Incidência , Avaliação das Necessidades , Papel do Profissional de Enfermagem , Medicina Estatal/normas , Reino Unido/epidemiologia , Instituições Filantrópicas de Saúde/organização & administraçãoRESUMO
There are some 130 pathology external quality assessment schemes available in the United Kingdom. Most are provided from within the National Health Service, but a few from the private sector. At the invitation of the Department of Health, Clinical Pathology Accreditation (UK) Ltd. has developed an accreditation system for these schemes. Accreditation is based on scheme organisers declaring compliance with 62 standards and an on-site inspection. As of the end of 2000, 105 schemes have been accredited. Most of the schemes in the disciplines of Clinical Biochemistry, Haematology, Immunology and Microbiology have now been accredited, but progress has been slower in non-numerical schemes in the disciplines of Cellular Pathology and Genetics.
Assuntos
Acreditação , Alergia e Imunologia/normas , Química Clínica/normas , Hematologia/normas , Microbiologia/normas , Patologia/normas , Genética/normas , Órgãos Governamentais , Humanos , Laboratórios/normas , Revisão por Pares , Garantia da Qualidade dos Cuidados de Saúde , Reino UnidoRESUMO
Allergy is common and the prevalence has increased substantially in the last 2-3 decades. There has been a particular increase in severe allergic disease, including anaphylaxis, food, drug and latex rubber allergy. Provision of allergy services in the NHS is extremely poor and there is a huge unmet need. Allergy is a full speciality, but there are few consultants and few trainees. Whilst other specialists have a role in the management of allergy, it is no longer adequate to devolve most of allergy care to them. Provision of allergy care must be lead by allergy specialists so that adequate standards of care can be achieved. The lack of care leads to morbidity, mortality and substantial cost to the NHS, much of which is avoidable. There is an urgent need for the creation of more consultant posts in allergy and this requires recognition by Trust Managers, Regional Commissioners and the Department of Health.